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SINTESIS DAN AKTIVITI BIOLOGI ANALOG 
BENZIMIDAZOLSEBAGAIPERENCAT ENZIM SIRTUIN 
 
ABSTRAK 
 
Bagi mencari perencat enzim sirtuin yang poten, 90 analog benzimidazol 
telah berjaya direka.Kaedah sintesis yang digunakan dalam projek ini mengambilkira 
langkah-langkah yang lestari.Sebatian4h (ethyl 2-(4-(piperidin-1-yl)phenyl)-1H-
benzo[d]imidazole-5-carboxylate)merupakanperencat enzim sirtuin yang paling baik 
dalam projek ini. Ia didapati merencat sirtuin-2 (SIRT2) lebih baik daripada sirtuin-1 
(SIRT1). Daripada profil sebatian dengan aktiviti perencatan SIRT1/SIRT2, 
perhubungan struktur dengan aktiviti boleh disimpulkan.Juga menarik perhatian ialah 
kemampuan sebatian4h untuk mengekang pertumbuhan sel kanser kolorektal. Selain 
daripada itu, ia juga mempunyai keupayaan untuk mencegah pertumbuhan sel kanser 
leukemia dan payudara. Pemodelan komputer turut digunakan untuk memberi 
penjelasan yang wajar terhadapkeputusan aktiviti yang diperolehi. Sebatian4h 
didapati boleh didokkan kedalam tapak aktif enzim SIRT2 dengan menggunakan 
struktur kristal (PDB: 3ZGV). Walau bagaimanapun, usaha untuk merasionalkan 
data aktiviti untuk SIRT1 tidak berjaya dilakukan dengan kaedah pemodelan 
komputer.Beberapa sifat-sifat kimia sebatian4h seperti kelarutan dalam air, 
kestabilan dan pendarfluor sebatian juga dikaji dengan teliti.Berdasarkan kajian 
literatur, sebatian4h merupakan perencat sirtuin pertama yang dilaporkan 
mempunyai sifat berpendarfluor.Ia merupakan kelebihan tambahan kerana boleh 
digunakan bagi memantau perubahan morfologi serta fenotip sel kanser.Keputusan 
yang dilaporkan dalam projek ini dengan jelasnya menunjukkan perhubungan antara 
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perencatan aktiviti sirtuin dengan kanser apabila 66.7% daripada sebatian yang aktif 
mempunyai aktiviti anti-kanser yang memberangsangkan.Inijuga 
membuktikanenzimsirtuinadalahsasaran analog benzimidazol yang dikaji.Sebatian 
yang mempunyai aktiviti perencatan sirtuin yang baik serta menunjukkan kesan 
sitotoksik seperti sebatian 4h merupakan calon utama pengubahasuaian demi 
meningkatkan aktiviti dan profil “drug-like” kerana penerokaan benzimidazol 
mungkin menghasilkan sebatian yang berguna dalam perawatan kanser.Walaupun 
penyelidikan yang lebih komprehensif masih diperlukan untuk mengetahui dengan 
lebih mendalam peranan enzim sirtuin terhadap kanser, perencatan enzim sirtuin 
merupakan strategi yang baru dan berdaya maju dalam terapi kanser. 
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SYNTHESIS AND BIOLOGICAL ACTIVITY OF BENZIMIDAZOLE 
ANALOGS AS SIRTUIN ENZYME INHIBITORS 
 
ABSTRACT 
 
 In the effort to search for potent sirtuin inhibitors, 90 benzimidazole analogs 
across 6 series were designed, synthesized and characterized. Compound 4h (ethyl 2-
(4-(piperidin-1-yl)phenyl)-1H-benzo[d]imidazole-5-carboxylate)was identified to be 
the most potent sirtuin inhibitor in this project with a preference for sirtuin-2 (SIRT2) 
inhibition over SIRT1. Based on the profile of the compounds along with their 
demonstrated SIRT1/SIRT2 inhibitory activities, a structure-activity-relationship was 
deduced for the benzimidazole moeity. Remarkably, compound 4h exhibited potent 
growth inhibitory effect on colorectal cancer cell lines. Apart from colorectal cancer, 
it was also found to possess antiproliferative activity against leukemia and breast 
cancer cell lines. Molecular docking approach was used to rationalize the observed 
activity. The SIRT2 crystal homology model (PDB: 3ZGV) was found to be able to 
accommodate compound 4h in its active site, thus supporting the notion that 4h was 
indeed able to strongly inhibit the SIRT2 activity. However, the structure activity 
relationship of the compounds towards observed SIRT1 inhibition was unable to be 
completely rationalized using similar method.In light of the potential of compound 
4h in combating cancer, some relevant physicochemical attributes of 4h such as 
water solubility, compoundstability andfluorescent properties were determined. 
Based on literature review, compound 4h is the first highly fluorescent sirtuin 
inhibitor reported so far. This is an added advantage as it could be useful in 
monitoring morphological as well as phenotype changes in cancer cells. In summary, 
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the results reported in this thesis clearly demonstrated a significant correlation 
between sirtuin inhibition and cancer as 66.7% of the synthesized compounds with 
potent sirtuin inhibitory activity possessed antiproliferative effect against cancer cells. 
Furthermore, it provided a proof of concept that sirtuin enzymes are indeed targets of 
benzimidazole derivatives.Compounds with potent sirtuin inhibition and which 
demonstrated cyototoxic effect such as 4h are prime candidates for further 
modifications to enhance the activity and drug-like profiles as exploration of the 
benzimidazole scaffold may eventually yield useful compounds in cancer 
treatment.Although more research is needed to further elucidate the role of sirtuins in 
cancer, sirtuin inhibition remains a new and viable strategy in cancer therapy. 
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CHAPTER ONE 
INTRODUCTION TO SIRTUIN BIOLOGY 
 
1.1  Sirtuins and histone deactylases (HDACs) 
Histone acetyl-transferases (HATs) are enzymes which add acetyl groups to 
lysine from histones while histone deacetylases (HDACs) remove the acetyl groups. 
Both HATs and HDACs play important roles in gene expression by regulating the 
acetylation and deacetylation of histones respectively (Simmons, 2008; Philips & 
Shaw, 2008).  
 
In general, HATs act as transcriptional gene activators as acetylation of lysine 
neutralizes the positive charge normally present and subsequently promotes a more 
relaxed chromatin structure by reducing affinity between histone and the negatively 
charged DNA. This indirectly renders DNA more accessible to transcription factors 
(Marks & Xu, 2009). On the contrary, HDACs promote a more condensed chromatin 
structure and act as transcriptional gene suppressor (Johnstone, 2002). Histone 
deacetylation represses gene transcription by increasing ionic interactions between 
the positively charged histones and negatively charged DNA, thus limiting its access 
to transcription factors. 
 
In humans, 18 HDAC enzymes have been identified, which can be 
subdivided into four classes (HDAC Class I-IV) primarily based on their homology 
to yeast HDACs (Blander & Guarante, 2004; Bhalla, 2005). Among these, class I, II 
and IV HDACs are dependent on Zn
2+
 for their deacetylase activity. The only 
exception is class III HDAC, or sirtuins, as they require NAD
+
 instead of Zn
2+
 as a 
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cofactor (North & Verdin, 2004; Michan & Sinclair, 2007). The role of NAD
+
 in the 
deacetylase activity of the Silent Information Regulator (SIR2)-like protein was first 
described in detail by Landry, Slama, and Sternglanz (2000). Then ADP-ribosyl 
transferase activity of sirtuins was considered a low efficiency side-reaction due to 
the partial decoupling of intrinsic deacetylation and acetate transfer to ADP-ribose. 
(Denu, 2005). More recently, mono-ADP-ribosyl transferase activity was found to be 
the main enzymatic activity of human Sirtuin-4 (SIRT4) and also human Sirtuin-6 
(SIRT6) (Liszt, Ford, Kurtev, & Guarante, 2005; Haigis et al., 2006). In general, the 
enzyme reactions that are catalyzed by sirtuins are depicted in Figure 1.1. 
 
 
Figure 1.1 Enzymatic reactions catalyzed by sirtuin enzymes. In addition to the 
deacetylation of lysine residues (A), other reaction mechanisms such as lysine 
demalonylation, desuccinylation, deglutarylation (B), and mono-ADP-ribosylation 
(C) have been reported. The members of the sirtuin family catalyzing the various 
reactions are given on the arrows. 
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1.2  The history of sirtuin 
The class III histone deacetylases (HDACs), or sirtuins include a group of 
proteins that are homologous with the yeast SIR2 family of proteins. Originally 
known as Mating-type regulator 1 (Mar1), SIR2 was discovered by Klar et al. in 
1979 through spontaneous mutation of the mating-type loci Hidden MAT Right 
(HMR) and Hidden MAT Left (HML) (Klar, Seymour & Macleod, 1979). SIR2 was 
later demonstrated to play a major role in silencing genes near telomeres. The silent 
regions at the telomeres and mating-type loci were later shown to be associated with 
histones that were hypoacetylated at the ε-amino group of N-terminal lysine residues 
(Braunstein, Rose, Holmes, Allis, & Broach, 1993). In 1999, Roy Frye had identified 
and characterized five of the human SIR2 homologues (SIRT1-5) and called the 
genes “sirtuin” (Fyre, 1999). In 2000, another two SIR2 homologues (SIRT6 and 
SIRT7) were added to the family (Fyre, 2000), making it a total of seven sirtuins 
having been identified in human (SIRT1-7). 
 
 
1.3  Overview of biochemical and catalytic activities of sirtuins 
Each sirtuin is characterized by an approximately conserved 275 amino acid 
catalytic core with unique additional N-terminal and/or C-terminal sequences of 
variable length (Figure 1.2) (Fyre, 2000).  
4 
 
 
Figure 1.2 Schematic representation of SIRT1-7. Each sirtuin is characterized by 
an approximately conserved 275 amino acid catalytic core (in yellow) with unique 
additional N-terminal and/or C-terminal sequences of variable length (in blue). 
 
 
The side chains are important as they are perceived to serve as “switches” for 
sirtuin activity. This is because the additional variable N- or C-terminal sequences 
flanking the catalytic core have been reported to enhance the activity by up to 45-
fold (Pan, Yuan, Brent, Ding, & Marmorstein, 2012) and lead to diverse subcellular 
localizations that contribute to the difference in biological functions (Figure 1.3).  
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Figure 1.3 Cellular localization and enzymatic activities of the mammalian 
sirtuins. SIRT1 is predominantly expressed in the nucleus and the cytoplasm. SIRT2 
is mainly expressed in the cytoplasm but may be shuttled to the nucleus during 
mitosis. SIRT3, SIRT4 and SIRT5 are mainly localized in the mitochondria. SIRT6 
and SIRT7 are confined to the nucleus. SIRT1, SIRT2 and SIRT3 possess 
deacetylase activity whereas SIRT4 modulates ADP-ribosylation activity. Apart from 
deacetylase activity, SIRT5 possess demalonylase and desuccinylase activities while 
SIRT6 possess ADP-ribosyltransferase, demyristoylase and depalmitoylase actions.  
 
 
Sirtuin-1 (SIRT1) is the direct homologue of the yeast SIR2 and is mainly 
located in the nucleus. It has a wide range of cellular functions such as modulating 
cell survival and regulating the transcriptional activities of NF-ĸB (Kauppinen, 
Suuronen, Ojala, Kaamiranta, Salminen, 2013), p53 (Luo, Su, Chen, Shiloh, & Gu, 
2000) and FOXO proteins (Berdichevsky & Guarante, 2006). Sirtuin-2 (SIRT2) 
resides mainly in the cytoplasm. SIRT2 has been shown to deacetylate a number of 
substrates in vitro, including α-tubulin (Dryden, Nahhas, Nowak, Goustin, & 
Tainsky, 2003; North, Marshall, Borra, Denu, & Verdin, 2003).  
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Sirtuin-3 (SIRT3) was the first sirtuin found to be localized in the 
mitochondria of mammalian cells (Onyango, Celic, McCaffery, Boeke, & Feinberg, 
2002). Although many studies have argued for an exclusively mitochondrial function 
of SIRT3 (Onyango et al., 2002; Schwer, North, Fyre, Ott, & Verdin, 2002), some 
reports have shown that SIRT3 shuttles to the nucleus (Scher, Vaquero, & Reinberg, 
2007; Iwahara, Bonasio, Narendra, & Reinberg, 2012). SIRT3 regulates the 
acetylation activity of metabolic enzymes such as acetyl-CoA-synthetase (ACS) 
(Hallows, Lee, & Denu, 2006). Another target of SIRT3, hydroxymethylglutaryl 
CoA synthase 2 (HMGCS2) regulates ketone body production, thus helping to 
supply energy to the brain during fasting (Shimazu et al., 2010). Another study by 
the same group of researchers also revealed a new function of SIRT3 in fatty acid 
oxidation (Hirschey et al., 2010). It was shown that SIRT3 deacetylates long-chain 
acyl CoA dehydrogenase (LCAD) and upregulates its enzymatic activity during 
fasting. In short, SIRT3 may be especially important under energy limitation 
conditions. 
 
Sirtuin-4 (SIRT4) is a mitochondrial sirtuin which is involved in metabolism. 
In contrast to SIRT3, SIRT4 has not been reported to possess deacetylation activity 
but only ADP-ribosylation activity (Haigis et al., 2006). It has been shown that 
SIRT4 can repress glutamate dehydrogenase in pancreatic β-cells and control the 
insulin secretion (Haigis et al., 2006). Interestingly, although SIRT3 and SIRT4 both 
play an important role in metabolic regulation, they have opposing roles in glutamate 
dehydrogenase regulation and fatty acid oxidation (Nasrin et al., 2010). 
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Localized in mitochondria, Sirtuin-5 (SIRT5) has weak deacetylase activity 
but does not appear to possess ADP-ribosyltransferase activity (Haigis et al., 2006). 
SIRT5 was originally reported to deacetylate carbamoyl-phosphate synthase 1 
(CPS1) and play a role in the regulation of urea cycle (Nakagawa, Lomb, Haigis, & 
Guarante, 2009). However, the demalonylation and desuccinylation actions of SIRT5 
on CPS1 and other proteins are now thought to be more prominent than its 
deacetylation activities (Du et al., 2011).  
 
Like SIRT1, Sirtuin-6 (SIRT6) is abundant in the nucleus. Biochemically, 
SIRT6 has been shown to demonstrate robust ADP-ribosyltransferase activity but 
only weak deacetylase activity (Liszt et al., 2005; Michishita et al., 2009). Pan and 
colleagues have shown that its deacetylation rate was approximately 1000 times 
weaker compared to other highly active sirtuins (Pan et al., 2011). Recently, SIRT6 
was shown to also possess demyristoylase and depalmitoylase activities (Jiang et al., 
2013). Similar to SIRT1, SIRT6 is a transcriptional regulator. Hence deficiency in 
SIRT6 may alter the expression of many downstream genes (Kawahara et al., 2011; 
Tennen & Chua, 2011). Some of SIRT6‟s target genes include nuclear factor-kappaB 
(NF-κB) as well as hypoxia-inducible factor 1-alpha (HIF1α) target genes among 
others (Kawahara et al., 2009; Zhong et al., 2010). 
 
Compared to other members of the sirtuin family, very little is known about 
Sirtuin-7 (SIRT7) which is predominantly expressed in the nucleus (Michishita, 
Park, Bumekis, Barrett, & Horikawa, 2005). It is associated with active rDNA and 
interacts with RNA polymerase I (Pol I) to stimulate transcription. SIRT7 expression 
is abundant in the liver, spleen and testes. Conversely its expression is found to be 
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low in the heart, brain and muscle (Ford et al., 2006). This indirectly correlates 
SIRT7 with growth as it is mostly found in abundance in highly proliferative tissues. 
 
In short, it has been shown that sirtuins are upstream enzymes which regulate 
hundreds of downstream enzymes. Table 1.1 lists some of the downstream targets of 
various sirtuins. By identifying the functions of these proteins and the downstream 
targets which they regulate, it will be easier in determining which diseases they may 
be useful in treating. 
 
Table 1.1 Some downstream targets of SIRT1-7. 
Downstream targets 
SIRT1 SIRT2 SIRT3 SIRT4 SIRT5 SIRT6 SIRT7 
 p53 
 NF-κB 
 FOXO 
 BCL6 
 CDH1 
 Tubulin 
 p53 
 FOXO 
 K-RAS 
 HIF-α 
 Skp2 
 p53 
 PPARα 
 GLUD1 
 Nrf2  COX-2 
 NF-κB 
 HIF-α 
 Mir125 
 p53 
 
 
 
1.4  Roles of sirtuins in cancer 
The involvement of sirtuins in carcinogenesis cannot be denied as have been 
demonstrated time and again in the past decade (Saunders & Verdin, 2007; Brooks 
&Gu, 2008; Lavu, Boss, Elliott, & Lambert, 2008). However, there is yet to be any 
consensus on the role of sirtuin in cancer owing to the complexity and diversity of 
their effects. Establishment of the mechanism played by sirtuin in this area remains 
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obscure. Although research on sirtuin has intensified in the past years, it only 
revealed the perplexed roles of sirtuins in promoting versus suppressing cancer. 
Although genes are generally classified as either tumor promoting or tumor 
suppressing, there are only limited number of genes which fall unambiguously into 
either one of these categories. The janus-face sirtuins exert their roles depending on 
different conditions such as the stage of cancer development and other variables 
which include tissue origin and the cancer microenvironment (Deng, 2009; Bosch-
Presegué & Vaquero, 2011; Roth & Chen, 2014).  
 
 
1.4.1  SIRT1 
SIRT1 remains the most controversial of all sirtuins when it comes to cancer 
therapy. SIRT1 has been demonstrated to be upregulated in several types of cancer, 
including colon cancer (Stünkel et al., 2007), prostate cancer (Huffman et al., 2007), 
pancreatic cancer (Zhao et al., 2011), acute myeloid leukemia (Bradbury et al., 2005) 
and skin cancer (Hida, Kubo, Murao, & Arase, 2007). In contrast, diminished SIRT1 
expression was found in many other cancer types including glioblastoma, bladder 
carcinoma, ovarian cancer and breast cancer (Wang et al., 2008), highlighting the 
perplexed role of SIRT1 in cancer.  
 
 The capability of SIRT1 as a tumor promoter can be examined across the 
hallmarks of cancer (Hanahan & Weinberg, 2011). The first evidence of SIRT1 
acting as tumor promoter came from experiments showing that SIRT1 deacetylates 
p53 at its C-terminal Lys382 residue (Vaziri et al., 2001) as loss of p53 tumor 
suppressor is very common in many cancer types. Apart from p53, there is evidence 
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of involvement of SIRT1 in epigenetic silencing of tumor suppressor genes and 
proteins such as secreted frizzled-related protein 1 (SFRP1), cadherin-1 (CDH1), 
E2F transcription factor 1 (E2F1) and B-cell lymphoma 6 (BCL6) resulting in 
resistance to cell death (Wang et al., 2006; Pruitt et al., 2006).  
 
Another key tumor suppressor family that is deacetylated by SIRT1 is the 
FOXO family of transcription factors (Brunet et al., 2004; Daitoku et al., 2004). One 
of the functions of the FOXO family of genes is their involvement in cell cycle 
control as well as DNA damage repair (Ho, Myatt, & Lam, 2008; Dansen & 
Burgering, 2008). Furthermore, SIRT1 deacetylation of FOXO3a has been reported 
to suppress FOXO3-mediated cell apoptosis which contributed to the promotion of 
cancer (Motta et al., 2004).  
 
Epithelial-mesenchymal-transition (EMT) which is a key step in 
morphogenesis is an essential factor in cancer metastasis. SIRT1 has been found to 
be a regulator of EMT in prostate (Byles et al., 2012) and gastric cancers (Zhang et 
al., 2013). In enabling replicative immortality through EMT, SIRT1 has been shown 
to deacetylate HIF (Eades et al., 2011; Dioum et al., 2009) in hypoxic environment, 
thereby enhancing glucose uptake and tumor cell survival.  
 
On the contrary, SIRT1 plays a role as tumor suppressor by maintaining 
genetic stability through chromatin regulation and DNA repair (Byles et al., 2010). 
An elegant study of SIRT1 overexpression in transgenic mice showed that increased 
SIRT1 expression by three-fold significantly improved healthy mouse aging (Fan & 
Luo, 2010). The data also showed that mice with upregulated SIRT1 expression 
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exhibit a reduction in carcinomas and sarcomas. Furthermore, in a liver cancer 
model, SIRT1 transgenic mice were less susceptible to liver cancer and showed 
greater protection from both DNA and metabolic damage relative to wild-type mice 
(Fan & Luo, 2010). 
 
In addition to genetic stability, SIRT1 may regulate other downstream genes 
via various pathways which contribute to its tumor suppressing function. SIRT1 has 
been shown to bind to NF-ĸB which is known to promote cell survival (Wang, Liu, 
Wang, & Zhang, 2009). SIRT1 deacetylates the p65/Rel-A subunit of NF-ĸB, thus 
inhibiting some related anti-apoptotic target genes such as cellular inhibitor of 
apoptosis-2 (cIAP-2) and B-Cell lymphoma-extra large (BCL-xL) (Yeung et al., 
2004). In line with its tumor suppressing function, SIRT1 acts on Breast cancer gene 
1 (BRCA1) to negatively regulate another anti-apoptotic gene, Survivin (Wang et al., 
2008). Furthermore, SIRT1 targeted and deacetylated H3K9 which promotes 
Survivin. Therefore, reduction of SIRT1 resulted in elevated Survivin levels and 
enhanced tumor growth. SIRT1 has also been identified as a tumor suppressor in oral 
cancer as Chen et al. (2014) showed the overexpression of SIRT1 blocked migration 
of Oral Squamous Cell Carcinoma (OSCC) cells in vitro by targeting Smad4 gene. 
 
 
1.4.2  SIRT2 
Similar to SIRT1, SIRT2 has both roles in tumor promotion and suppression. 
SIRT2 was reported to be a tumor suppressor in gliomas (Hiratsuka et al., 2003) and 
melanomas (Lennerz et al., 2005) while found to be overexpressed in acute myeloid 
leukemia (Dan et al., 2012) and hepatocarcinomas (Xie, Jung, & Nam, 2011).  
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Most studies have linked the role of SIRT2 as a tumor suppressor to its 
mitotic checkpoint function (Dryden et al., 2003). SIRT2 was reported to prevent 
cells from progressing into mitosis in the presence of microtubule poisons, 
potentially through the regulation of chromatin condensation (Inoue, Hiratsuka, 
Osaki, & Oshimura, 2007).  
 
A study by Kim et al. (2011) showed that SIRT2-deficient mice are more 
susceptible to tumor development due to abnormal chromosomal segregation. A 
reduction of SIRT2 mRNA expression was also reported in breast cancer and 
hepatocellular carcinoma (HCC) (Kim et al., 2011). Another recent study by Nguyen, 
Lee, Lorang-Leins, Trepel, & Smart (2014) showed that SIRT2 interacts with β-
catenin to inhibit Wnt signaling. In SIRT2 dificient MEFs, an up-regulation of matrix 
metalloproteinase 9 (MMP9) and decreased CDH1 expression was observed, leading 
to increase cell migration and invasion (Nguyen et al., 2014). These indirectly 
suggest a promotion of cancer metastasis. 
 
Conversely, the capability of SIRT2 to promote cancer can be seen through 
many, if not all hallmarks of cancer. Similar to SIRT1, SIRT2 deacetylates and 
downregulate p53 tumor suppressor (van Leeuwen et al., 2013) and K-RAS gene 
(Yang et al., 2013) to evade growth suppressors and to promote cell survival in 
response to genotoxic stress (Li et al., 2011). Wang et al. (2012) showed that 
deacetylation of FOXO3 by SIRT1/SIRT2 results in its degradation, thereby 
contributing to the promotion of cancer. 
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Altogether, these data suggested both tumor promoter and suppressor role for 
SIRT1 and SIRT2. It seems very likely that under normal circumstances, 
SIRT1/SIRT2 may promote cell survival via DNA repair or inhibition of apoptosis. 
This in turn suppresses tumorigenesis. However, when the level of cell damage 
crosses a certain threshold, tumor cells co-opt with SIRT1/SIRT2-regulated 
pathways to promote cell proliferation and resist apoptosis (Figure 1.4). As such, the 
role of SIRT1/SIRT2 in cancer is very much dependent on cellular and molecular 
contexts. This scenario could very much be applied to other sirtuins which have both 
tumor promoter and tumor suppressor activities. 
 
Figure 1.4 Dual role of sirtuin in cancer. Below the stress threshold, sirtuin 
promotes DNA repair and ultimately cell survival. Above chronic stress threshold, 
sirtuin induces tumor formation and cancer. 
 
 
1.4.3  SIRT3 
Similar to SIRT1 and SIRT2, SIRT3 displays a dual function role in cancer. 
Under normal conditions it acts as a tumor suppressor and promotes apoptosis 
(Allison & Milner, 2007; Sundaresan, Samant, Pillai, Rajamohan, & Gupta, 2008) 
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whereas under stress conditions or DNA damage, it seems to act as a tumor 
promoter. Low levels of endogenous SIRT3 expression have been reported in breast 
cancer (Kim et al., 2010). Its role as tumor suppressor was first evidenced through 
the promotion of mammary tumor formation in SIRT3 knockdown mice (Kim et al., 
2010). Consistently, Bell, Emerling, Ricoult and Guarante (2011) later demonstrated 
that knockdown of SIRT3 in both osteosarcoma and colon cancer resulted in 
increased tumor size. It was demonstrated that one major tumor suppression 
mechanism of SIRT3 was through the modulation of Reactive Oxygen Species 
(ROS) (Finley et al., 2011). Elevation in ROS has been reported to stabilize HIF-α. It 
thereby contributed positively to tumorigenesis by increasing the expression of HIF-
dependent genes such as Vascular Endothelial Growth Factor (VEGF) and 
phosphoglycerate kinase-1 (PGK-1) (Bell, Emerling, Ricoult, & Guarente, 2011; 
Schumacker, 2011). 
 
Recently, Inuzuka et al. (2012) discovered a novel tumor suppressor function 
for SIRT3 through deacetylation of Skp2. Skp2 functions as an E3 ubiquitin ligase 
and it was shown to target tumor suppressors such as p21, p27 and E-cadherin 
(Frescas & Pegano, 2008; Tiwari, Ghedolf, Tatari, & Christofori, 2012). 
Deacetylation of Skp2 by SIRT3 prevents Skp2 from targeting these tumor 
suppressors and subsequently subdues tumorigenesis. E-cadherin is often linked to 
EMT and metastasis and its reduction has been observed in many cancer types 
(Tiwari et al., 2012). Very recently, Huang et al. (2014) also found a tumor 
suppressive role for SIRT3 in gastric cancer.  
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Conversely, there is mounting evidence that mitochondrial SIRT3 acts as a 
tumor promoter. SIRT3 was found overexpressed in several human oral cancer cells 
(Alhazzazi et al., 2011). Downregulation of SIRT3 in these cells inhibited OSCC cell 
growth and enhanced the effect of chemotherapeutic drugs. In addition, SIRT3 
downregulation in OSCC cells in vivo resulted in reduced tumor size in mice, further 
confirming the role of SIRT3 as a tumor promoter in oral cancer (Alhazzazi et al., 
2011). SIRT3 overexpression was also able to rescue p53-induced cell growth arrest 
in bladder cancer (Li et al., 2010). SIRT3 was found to complex with p53 during the 
initial stages of its expression. This suggests that SIRT3 may partially reduce the 
activity of p53 to enact growth arrest and senescence. Taken together, these findings 
provide some evidence that SIRT3 may have a cell-protective role under stress to 
promote cancer cell growth. 
 
 
1.4.4  SIRT4 
Recent advances have shed some light on the roles of SIRT4 in cancer. Many 
studies have pointed towards SIRT4 as a tumour suppressor. Jeong et al. (2013) first 
reported the tumor suppressive role for SIRT4 through the inhibition of 
mitochondrial glutamine metabolism. Their data showed that the deletion of SIRT4 
increased glutamine-dependent proliferation and stress-induced genomic instability, 
resulting in tumorigenesis. Moreover, SIRT4 knockout mice spontaneously develop 
lung tumors. In continuation of their studies, the authors reported that due to the 
inhibition of mitochondrial glutamine metabolism by SIRT4, MYC-induced B cell 
lymphomagenesis was repressed (Jeong et al., 2013). Consistently, Csibi et al. (2013) 
reported that expression of SIRT4 in cells with activated mechanistic Target 
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OfRapamycin Complex 1 (mTORC1) repressed the glutamine anaplerosis process 
and blocked the growth of cells. It was also found that overexpression of SIRT4 in 
MEFs lacking both TSC2 and p53 had reduced tumor proliferation (Csibi et al., 
2013). These studies, albeit few, pointed to a tumor suppressive role for SIRT4. 
 
 
1.4.5  SIRT5 
Though not yet extensively characterized, some studies have recently linked 
SIRT5 to cancer. SIRT5 was found to promote cancer growth and facilitate drug 
resistance in non-small cell lung cancer (Lu, Zuo, Feng, & Zhang, 2014). In the 
process, Nuclear factor erythroid 2-related factor (Nrf2), a core transcription factor 
for lung cancer growth and drug resistance, was identified as a target of SIRT5. Due 
to the scarcity of reports in this area, there is a need for further research to better 
understand the role of SIRT5 in tumorigenesis. 
 
 
1.4.6  SIRT6 
As for SIRT6, most current evidence suggests that it acts as a tumor 
suppressor, considering its function in maintaining genome stability. SIRT6 is 
frequently deleted or significantly reduced in numerous tumors such as pancreatic 
and colorectal tumors (Van Meter, Mao, Gorbunova, & Seluanov, 2011). It was 
found that induction of SIRT6 overexpression in a variety of cancer cell lines 
resulted in massive apoptosis (Sebastian et al., 2012). Knockdown of SIRT6 resulted 
in increased tumor incidence in colon cancer model as shown by Sebastian et al. 
(2012). This was mediated through the reduction of MYC activity and activation of 
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glycolysis. However, the tumor suppressor role of SIRT6 has been challenged with a 
recent finding by Ming et al. (2014). They found that SIRT6 promotes COX-2 
expression and acts as an oncogene in skin cancer.  
 
 
1.4.7  SIRT7 
SIRT7 level is elevated in several cancer types such as thyroid (de Nigris et 
al., 2002), breast (Ashraf et al., 2006), liver (Kim et al., 2012) and colon (Yu et al., 
2014) cancer. Substrate for SIRT7 includes mir-125 (Kim et al., 2012) and p53 
(Vakhrusheva et al., 2008) among others. Although there is limited information 
which links SIRT7 to cancer, it is the only sirtuin to date where all current studies 
points to a tumor promoting role. 
 
 
1.5  Different classes of sirtuin inhibitors 
Sirtuins first gained prominence when it was reported that their activation 
might be related to longevity (Kaeberlein, McVey, & Guarente L., 1999; Ghosh, 
2008). However, there have since been conflicting views on that matter and the 
attention has been shifted to sirtuin inhibitors as they have been linked to the 
pathogenesis of cancer (Martinez-Pastor, & Mostoslavsky, 2012). Although sirtuin 
overexpression might be beneficial in preventing cancers, situin activators 
(especially SIRT1 activators) are seldom touted as potential anti-cancer agents. In 
fact, most if not all of the small molecule sirtuin modulators which showed anti-
cancer properties are inhibitors. 
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In the past, the development of sirtuin inhibitors was focused mainly on 
SIRT1−3. This was mainly due to the limited possibilities in determining the 
inhibitory activity against SIRT4−7 using the enzymatic assays as they only show 
weak or no deacetylation activity to known protein substrates. However, the 
discovery of enzymatic activities other than deacetylation for SIRT5 and SIRT6 and 
the expanding list of known protein targets for SIRT4−7 enable now the 
development of inhibitors for these isoforms. However, as SIRT1 and SIRT2 remain 
two of the best characterized sirtuins, most sirtuin inhibitors developed currently are 
targeted towards these two isoforms. 
 
 
1.5.1  Nicotinamide derivatives 
Nicotinamide (Figure 1.5), which is a physiological inhibitor of Sir2, was 
shown to inhibit SIRT1 and SIRT2 with IC50 values of approximately 50 µM and 
100 µM respectively (Tervo et al., 2004). Initial studies reported nicotinamide to be a 
non-competitive inhibitor of SIRT1 and SIRT2 that interacts with the C-pocket 
(nicotinamide pocket) in the binding site (Bitterman, Anderson, Cohen, Latorre-
Esteves, & Sinclair, 2002). However, later discoveries suggest that the probable 
interaction could be due to reverse reaction of nicotinamide with O-alkylamidate I 
(Sauve, Wolberger, Schramm, & Boeke, 2006). There could, however, be limited 
potential to inhibitors of this class as further modifications to nicotinamide aimed to 
increase the potency against SIRT1/SIRT2 inhibition proved unsuccessful (Jackson, 
Schmidt, Oppenheimer, & Denu, 2003; Schmidt, Smith, Jackson, & Denu, 2004). 
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Figure 1.5 Structure of nicontinamide 
 
 
1.5.2  Suramin and its analogs 
Suramin (Figure 1.6) is a symmetric polyanionic naphthylureaurea. It was 
discovered to have sirtuin inhibitory activity during a screening for SIRT1 activators 
(Howitx et al., 2003). It is a potent SIRT1 inhibitor with IC50 value of 0.3 µM (Trapp 
et al., 2007). By replacing the central symmetrical bis(meta-carboxyphenyl)urea 
moeity by an isophthalic acid, Trapp et al. (2007) have exploited the suramin 
backboned and managed to identify a selective SIRT1 inhibitor (NF675, Figure 1.6) 
with IC50 value of 0.1 µM. However, the use of suramin as potent sirtuin inhibitor 
and future therapeutic application was set aback by its nephrotoxicity (Figg et al., 
1994) and neurotoxicity at high concentration (Gill, Hobday, & Windebank, 1995).  
 
20 
 
HN
NaO3S
SO3Na
O
N
H
H
N
H
N
N
H
NH
SO3Na
SO3Na
SO3NaONaO3S
O O
O
Suramin
HN
NaO3S
SO3Na
O
N
H
N
H
NH
SO3Na
SO3Na
SO3NaONaO3S
O O
NH2
NF675  
Figure 1.6 Structure of Suramin and NF675. 
 
 
1.5.3  Splitomicin and its analogs 
Splitomicin (Figure 1.7) was discovered to inhibit Sir2p and HST1 in 
micromolar level in a cell-based screen (Bedalov, Gatbonton, Irvine, Gottschling, & 
Simon, 2001). As this molecule is small (molecular mass < 200), it represents an 
attractive lead model for histone deacetylase inhibitors such as sirtuins. It was found 
that different structural changes to the splitomicin scaffold accounted for inhibitor 
selectivity (Hirao et al., 2003). Based on the knowledge gathered earlier, more potent 
inhibitors of human subtypes were later developed. An alpha-phenyl splitomicin with 
a bromo-subtituent in 8-position coded HR73 (Figure 1.7) was found to inhibit 
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SIRT1 with an IC50 value of 5 µM and it was shown to decrease HIV transcription 
via acetylation of Tat protein (Pagans et al., 2005). Similarly, Neugebauer and co-
workers also screened a number of splitomicin analogs and they too managed to 
identify SIRT2 selective inhibitors in the low micromolar range (Neugebauer et al., 
2008). Through this work, the acetyllysine pocket was identified as the binding site 
for splitomicin and SIR2p. Nevertheless, it was noted that splitomicin and its analogs 
did not show potent anti proliferative activities towards MCF-7 breast cancer cells 
(Neugebauer et al., 2008). More recent splitomicin derivatives are also not potential 
therapeutic leads as they consist of metabolically unstable groups and are generally 
very lipophilic in nature (Freitag et al., 2011). 
O
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Figure 1.7 Structure of Splitomicin and HR73. 
 
 
1.5.4  Hydroxynaphthaldehyde derivatives 
Certain compounds bearing the hydroxynaphthaldehyde scaffold have been 
found to possess sirtuin inhibitory activities. Sirtinol (Figure 1.8), one of the first 
synthetic sirtuin inhibitors, was identified during a high-throughput phenotype 
screening for yeast SIR2 inhibitor (Grozinger, Chao, Blackwell, Moazed, & 
Schreiber 2001). It showed an IC50 of 68 µM for yeast SIR2p. It was further 
evaluated for human sirtuin inhibitory activities and is now considered a non-
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selective sirtuin inhibitor with an IC50 range of 37.6-131 µM and 38-58 µM for 
SIRT1 and SIRT2 respectively (Lawson et al., 2010). It has been suggested that 2-
hydroxy-1-naphthoic acid, which is formed by oxidation of 2-hydroxy-1-
naphthaldehyde is responsible for the observed activity of sirtinol (Dai, Hayashi, 
Nozaki, Cheng, & Zhao, 2005). Some derivatives of sirtinol have also been evaluated 
for their sirtuin inhibitory activities such as those reported by Mai et al. (2005). It 
was found that both the (R)- and (S)- enantiomers exhibit similar SIRT1 and SIRT2 
inhibition potency as racemic sirtinol. However, when the phenylethylacetamide 
group was shifted to the para position, the SIRT2 inhibitory activity improved (Mai 
et al., 2005). 
 
Salermide (Figure 1.8), a sirtinol analogue with “reverse amide” structure, 
was generated after taking into consideration molecular docking prediction (Lara et 
al., 2009). It also showed inhibitory effect for both SIRT1 (IC50 = 76.2 µM) and 
SIRT2 (IC50 = 45 µM) (Peck et al., 2010). More importantly, it was found to have 
apoptotic effect towards certain cancer cells (Lara et al., 2009).  
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Figure 1.8 Structure of Sirtinol and Salermide 
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Another sirtuin inhibitor with hydroxynaphthaldehyde moeity is cambinol 
(Figure 1.9). It is a pan SIRT1/SIRT2 inhibitor with IC50 values of 56 µM and 59 µM 
for SIRT1 and SIRT2 respectively (Heltweg et al., 2006). Although the in vitro 
investigation did not point to an extremely potent sirtuin inhibitory activity, it was 
nevertheless a strong lead compound as treatment of BCL6-expressing Burkitt 
lymphoma cells with cambinol led to apoptosis in vivo and also in mouse xenograft 
model. Due to its potential, various derivatives of cambinol have been designed, 
synthesized and evaluated in the search for more potent sirtuin inhibitors. More 
recent works have reported cambinol derivatives having IC50 values in the low 
micromolar range (Medda et al., 2009; Medda et al., 2011). Furthermore, recent 
optimization of cambinol structure has resulted in the identification of pyrazolone 
and isoxazol-5-one based analogues (coded 8, 17 and 24) which are isoform selective 
sirtuin inhibitors (Figure 1.9) (Mahajan et al., 2014).   
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Figure 1.9 Structure of cambinol and other sirtuin inhibitors with the 
hydroxynaphthaldehyde moeity. 
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1.5.5  Thiobarbiturates derivatives 
Thiobarbiturates are structurally related to cambinol, with thiourea moiety an 
intergral part of their structure. The first seven active inhibitors of this scaffold were 
uncovered in a virtual screening of over 300,000 compounds in Chembridge database 
(Uciechowska et al., 2008). Through molecular docking, these compounds were 
postulated to interact with the nicotinamide binding pocket analogous to cambinol. 
These compounds are generally unselective with regards to SIRT1 and SIRT2 with 
inhibition potency in micromolar levels (Uciechowska et al., 2008). Based on the 
molecular simulation data generated, several novel thiobarbiturates were synthesized, 
some of them showing SIRT1/SIRT2 selectivity based on different substituents 
attached to the thiourea substructure (Uciechowska et al., 2008). 
 
 
1.5.6  Indole derivatives 
Among the most potent and selective SIRT1 inhibitor identified to date is 
EX-527 (Figure 1.10), which is based on the indole structure. It was discovered 
during a fluorescent-based high-throughput screening by Napper et al. (2005). EX-
527 showed remarkable SIRT1 inhibition potency with IC50 value of 100 nM. 
Evaluation of its stereochemistry through kinetic studies as well as crystal analysis 
revealed that the (S)-enantiomer is the active isomer (Zhao et al., 2013). 
Furthermore, refined crystal analysis by Gertz et al. (2014) indicated that EX-527 
requires NAD
+
 for its inhibition activity and it occupies the nicotinamide binding site 
in SIRT1. EX-527 was found to increase the acetylation level of p53 but has no 
effect on cell survival after DNA damage (Solomon et al., 2006). It also failed to 
induce cell death in a separate study (Peck et al., 2010).  
